ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

4:30PM-6:00PM
Abstract Number: 899
Neutrophil Gene Signature and Low Density Granulocyte Subsets Associate with Coronary Plaque Burden and Vascular Inflammation in Systemic Lupus Erythematosus
2017 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lecture
4:30PM-6:00PM
Abstract Number: 947
Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics I
4:30PM-6:00PM
Abstract Number: 914
Occupational Exposure to Combustion Products and Risk of Developing Rheumatoid Arthritis
Epidemiology and Public Health II: Non-Genetic Risk Factors for Incident Disease
4:30PM-6:00PM
Abstract Number: 928
Online Consultation for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool: A Study of Medical Economics
ARHP Clinical Practice/Patient Care/Health Services Research
4:30PM-6:00PM
Abstract Number: 925
Open-Source Conensus-Based Models to Improve the Cost-Effectiveness of Rheumatology Care
ARHP Clinical Practice/Patient Care/Health Services Research
4:30PM-6:00PM
Abstract Number: 953
Persistence of Pathogenic CD4 Memory T Cells Revealed through Cytometry Time of Flight in Juvenile Idiopathic Arthritic Patients with Disease Resurgence upon Withdrawal of Anti-TNFA Biologics
T Cell Biology and Targets in Autoimmune Disease
4:30PM-6:00PM
Abstract Number: 915
Pesticide Exposure and Risk of Systemic Lupus Erythematosus in an Urban Population of Predominantly African-American Women
Epidemiology and Public Health II: Non-Genetic Risk Factors for Incident Disease
4:30PM-6:00PM
Abstract Number: 924
Prevalence of Juvenile Idiopathic Arthritis in the Alaska Native Population
Healthcare Disparities in Rheumatology
4:30PM-6:00PM
Abstract Number: 917
Prospective Association of Metabolic Syndrome with Incident Symptomatic Interphalangeal Osteoarthritis but Not Thumb Based or Erosive Hand Osteoarthritis
Epidemiology and Public Health II: Non-Genetic Risk Factors for Incident Disease
4:30PM-6:00PM
Abstract Number: 905
Regenerating Cartilage and Reversing Osteoarthritis (OA) Stimulation of Adenosine A2A Receptors (A2AR) Increases Cartilage Volume and Matrix in Vitro and In Vivo
Biology and Pathology of Bone and Joint
4:30PM-6:00PM
Abstract Number: 926
Relationship of Traumatic Knee Injuries to Early-Onset Knee Osteoarthritis in Young Military Officers
ARHP Clinical Practice/Patient Care/Health Services Research
4:30PM-6:00PM
Abstract Number: 935
Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Osteoarthritis – Clinical Aspects I: Pain and Functional Outcomes
4:30PM-6:00PM
Abstract Number: 941
Ro/SSA Autoantibody Exposed Neonates Have an Expansion of NK Cells and a Discernible Type II IFN Signature with High IFNγ in Peripheral Blood
Pediatric Rheumatology – Pathogenesis and Genetics
4:30PM-6:00PM
Abstract Number: 901
Role of Epstein Barr Virus Serologic Reactivation in Transitioning to Systemic Lupus Erythematosus in at Risk Individuals
2017 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lecture
4:30PM-6:00PM
Abstract Number: 942
Role of the Pyrin Inflammasome in Resistance to Yersinia Pestis: A Possible Selective Advantage for Carriers of MEFV Mutations
Pediatric Rheumatology – Pathogenesis and Genetics
  • «Previous Page
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology